The following represents disclosure information provided by authors of this abstract. The Genitourinary Cancers Symposium Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Everolimus in patients with metastatic renal cell carcinoma refractory to VEGF-targeted therapy: REACT subgroup analysis of prior therapy.
James M. G. Larkin
Consultant or Advisory Role - Novartis
Research Funding - Novartis
Christian U. Blank
Research Funding - Novartis
Petri Bono
Honoraria - Novartis
Research Funding - Novartis
Svetozar Gogov
Employment or Leadership Position - Novartis
Ashok Panneerselvam
Employment or Leadership Position - Novartis
Carlos A. Garay
Employment or Leadership Position - Novartis
Viktor Grünwald
Consultant or Advisory Role - Novartis
Honoraria - GlaxoSmithKline; Novartis; Pfizer; Roche
Research Funding - Novartis